Congratulations to Dr. Leon Coleman for receiving the prestigious 2025 ASPET Division for Neuropharmacology Early Career Award!
Dr. Coleman is receiving this award in recognition of his research, teaching and lasting contributions to pharmacology.
From the ASPET Award website:聽“Dr. Coleman has a history of making pioneering discoveries in the field of neuropharmacology, particularly Alcohol Use Disorder (AUD) and Alzheimer鈥檚 disease (AD) research. Recently, he has focused on finding novel regulators of immune pathology for alcohol abuse, Alzheimer’s disease, and severe burn injury. Dr. Coleman has found that heavy alcohol use promotes Alzheimer鈥檚 pathology through persistent activation of microglia leading to the disruption of neuronal lipid metabolism. He identified the loss of neuronal lysosomal acid lipase as a fundamental feature of the progression of Alzheimer鈥檚 disease that is enhanced by heavy alcohol use and midlife obesity. This has resulted in a US patent, and the development of novel PET ligands for the early diagnosis of Alzheimer鈥檚 disease. His work has identified extracellular vesicles are fundamental drivers of immune dysfunction in AUD and burn injury. The targeted removal of these detrimental vesicles is now under investigation as a novel immunotherapy approach.”
“The award will be presented by the Division for Neuropharmacology on April 5, 2025, during the ASPET 2025 Annual Meeting in Portland, Ore. Additionally, Dr. Coleman has been invited to give a lecture on his work as part of the annual meeting.
~the above two quotes are excerpts from the